Literature DB >> 4041330

Anticonvulsant therapy and cortisol elimination.

P J Evans, R F Walker, J R Peters, J Dyas, D Riad-Fahmy, J P Thomas, E Rimmer, L Tsanaclis, M F Scanlon.   

Abstract

The effect of anticonvulsant therapy on early morning concentration of cortisol in saliva and plasma was assessed in a group of epileptic patients receiving regular phenytoin medication and the results compared with those obtained from a group of normal subjects not receiving drug therapy. Values of cortisol in matched samples of plasma (331 +/- 23 nmol l-1, mean +/- s.e. mean, n = 6) and saliva (11.4 +/- 0.9 nmol l-1, mean +/- s.e. mean, n = 9) provided by epileptics did not differ significantly from those in the plasma (334 +/- 41 nmol l-1, mean +/- s.e. mean) and saliva (12.0 +/- 2.0 nmol-1, mean +/- s.e. mean) of healthy volunteers (n = 12). Six anticonvulsant-treated epileptics, together with six age and sex matched normal volunteers, each received intravenous dexamethasone (1 mg h-1) to determine the half-life of cortisol in plasma and saliva. In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers. In patients, the half life of cortisol and antipyrine showed a significant correlation (r2 = 0.75, P less than 0.05 plasma, r2 = 0.71, P less than 0.05 saliva). The antipyrine half-life in saliva was reduced significantly (P less than 0.02) and the antipyrine clearance rate, increased significantly (P less than 0.005) in the treated epileptic group, reflecting drug-induced microsomal enzyme production.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4041330      PMCID: PMC1400686          DOI: 10.1111/j.1365-2125.1985.tb05042.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

2.  Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma.

Authors:  S M Brooks; E E Werk; S J Ackerman; I Sullivan; K Thrasher
Journal:  N Engl J Med       Date:  1972-05-25       Impact factor: 91.245

3.  Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man.

Authors:  A W Meikle; W Jubiz; S Matsukura; C D West; F H Tyler
Journal:  J Clin Endocrinol Metab       Date:  1969-12       Impact factor: 5.958

4.  A simple, direct radioimmunoassay for plasma cortisol, featuring a 125I radioligand and a solid-phase separation technique.

Authors:  D Riad-Fahmy; G F Read; S J Gaskell; J Dyas; R Hindawi
Journal:  Clin Chem       Date:  1979-05       Impact factor: 8.327

5.  Radioimmunoassay of ACTH in plasma.

Authors:  S A Berson; R S Yalow
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

6.  Effect of diphenylhydantoin on cortisol kinetics in humans.

Authors:  Y Choi; K Thrasher; E E Werk; L J Sholiton; C Olinger
Journal:  J Pharmacol Exp Ther       Date:  1971-01       Impact factor: 4.030

7.  Use of saliva for monitoring unbound free cortisol levels in serum.

Authors:  T Umeda; R Hiramatsu; T Iwaoka; T Shimada; F Miura; T Sato
Journal:  Clin Chim Acta       Date:  1981-03-05       Impact factor: 3.786

8.  Diphenylhydantoin inhibits the thyrotropin response to thyrotropin-releasing hormone in man and rat.

Authors:  M I Surks; K W Ordene; D N Mann; M H Kumara-Siri
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

9.  Salivary cortisol assays for assessing pituitary-adrenal reserve.

Authors:  J R Peters; R F Walker; D Riad-Fahmy; R Hall
Journal:  Clin Endocrinol (Oxf)       Date:  1982-12       Impact factor: 3.478

10.  Studies on dexamethasone metabolism in man: effect of diphenylhydantoin.

Authors:  N Haque; K Thrasher; E E Werk; H C Knowles; L J Sholiton
Journal:  J Clin Endocrinol Metab       Date:  1972-01       Impact factor: 5.958

View more
  3 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

3.  Anticonvulsants delaying the diagnosis of Cushing's syndrome in a patient who presents with schizophrenia.

Authors:  Xin Zhao; Harrison X Bai; Li-Ming Tan; Li Yang
Journal:  Chin Med J (Engl)       Date:  2015-03-05       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.